In Week of Mar 28, 2026, Granules India Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +12.7% relative strength. Fundamentals: Average. On a 6-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Peptide business expected to move toward EBITDA breakeven in FY27 after current losses
Impact: +₹80 Cr revenue
“Sanjay Kumar: 'In addition, if all goes well with Godala Force, we'll have our launches in place. That will also facilitate the growth.'”
What: Planned maintenance in Q3 to drive higher deliveries and revenue in Q4
Impact: +₹50 Cr revenue
“Management: 'The benefit of this increased activity are expected to translate as deliveries conversion in the next quarter, that is the Q4.'”
What: Gagillapur facility remediation completion removing regulatory constraints
Impact: +₹40 Cr revenue
“Company announcement: 'remediation plans on track and expected formal feedback after documentation submission'”
Earnings deceleration risks from management commentary
Trigger: Regulatory delays or production issues
Impact: -300 bps margin impact
Management view: Sanjay Kumar: 'This quarter is 33 crores to share... quarter on quarter, last quarter it was 28 and the previous quarter also around 28, 29.'
Monitor: Peptide business EBITDA
Key quotes from recent conference calls
“We reported revenues of 1388 crore, a 22% increase year on year. EBITDA was 308 crores growing 34% over the same period last year. Margins improved meaningfully driven by disciplined execution and better operating leverage. — Management”
“Also during the quarter Q3 we incurred high operating cost on account of planned maintenance activities and additional shifts towards the key customer project. The benefit of this increased activity are expected to translate as deliveries conversion in the next quarter, that is the Q4. — Management”
“Right now we are going to be increasing capacities and catering to all the awards that we have in the US and to the other markets. So just the operational efficiencies will increase, productivity will increase and that will certainly increase the numbers going forward. — Sanjay Kumar”
“Revenue growth was broad based with strong contribution of formulation business in North America and Europe. — Management”
Forward-looking targets from management for next_2_4_quarters
Key Milestones
• Peptide business EBITDA breakeven
• FDA remediation completion
• Q4 revenue conversion from Q3 maintenance
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +22% | +6% | Stable |
| PAT (Net Profit) | +27% | +7% | Stable |
| OPM | 22.0% | +200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Granules India Ltd's latest quarterly results (Dec 2025) show
Granules India Ltd's profit is growing with an stable trend.
Granules India Ltd's revenue growth trend is stable.
Granules India Ltd's operating margin is stable.
Granules India Ltd's long-term compounding rates
Granules India Ltd's earnings growth is stable with mixed signals on a sequential basis.
Granules India Ltd's trailing twelve month (TTM) performance
Granules India Ltd appears significantly overvalued based on our fair value analysis.
Granules India Ltd's current PE ratio is 27.9x.
Granules India Ltd's current PE is 27.9x.
Granules India Ltd's price-to-book ratio is 3.8x.
Granules India Ltd is rated Average with a fundamental score of 48.99/100. This score is calculated from objective financial metrics
Granules India Ltd has a debt-to-equity ratio of N/A.
Granules India Ltd's return ratios over recent years
Granules India Ltd's operating cash flow is positive (FY2025).
Granules India Ltd's current dividend yield is 0.24%.
Granules India Ltd's shareholding pattern (Feb 2026)
Granules India Ltd's promoter holding has decreased recently.
Granules India Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Granules India Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
Granules India Ltd has 3 key growth catalysts identified from recent earnings analysis
Granules India Ltd has 1 key risk worth monitoring
In Q3 FY26, Granules India Ltd's management highlighted
Granules India Ltd's management has provided the following forward guidance for next_2_4_quarters
Based on quantitative research signals, here is why Granules India Ltd may be worth studying
Granules India Ltd investment thesis summary:
Granules India Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
